

Amendments to the Claims:

The following listing of claims replaces all prior versions, and listings, of claims in the application:


Listing of Claims:

1-36. (canceled)

37. (currently amended) A composition of matter comprising as an admixture at least one compound selected from group (i) (+)-(2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol or a salt thereof with a physiologically tolerated acid and oxybutynin;

wherein group (i) consists of:

~~1-phenyl-3-dimethylamino-propane compounds corresponding to formula I~~



wherein

X is OH;

~~R¹ is chosen from C₁₋₄-alkyl, unbranched, saturated and unsubstituted;~~

~~R² and R³ in each case independently of one another are chosen from H or C₁₋₄-alkyl, unbranched, saturated and unsubstituted;~~

~~R⁹ to R¹³ in each case independently of one another are chosen from H and OR¹⁴;~~

~~where R¹⁴ is C₁₋₆-alkyl, unbranched, saturated and unsubstituted~~

or a salt of ~~any of the foregoing thereof~~ with a physiologically tolerated acid at dosages that provide a synergistic effect for the treatment of urinary incontinence.

38. (withdrawn-currently amended) The composition of matter of claim 37, wherein one or more of ~~said at least one compound selected from group (i) (+)-~~ (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol and oxybutynin is present in the form of a free base.

39. (currently amended) The composition of matter of claim 37, wherein ~~one or more of said at least one compound selected from group (i) and~~ oxybutynin is present in the form of a pure enantiomer ~~or pure diastereoisomer.~~

40. (withdrawn-currently amended) The composition of matter of claim 37, wherein ~~one or more of said at least one compound selected from group (i) and~~ oxybutynin is present in the form of a mixture of stereoisomers.

41. (withdrawn-currently amended) The composition of matter of claim 40, wherein ~~one or more of said at least one compound selected from group (i) and~~ oxybutynin is present in the form of a racemic mixture.

42-56. (canceled)

57. (currently amended) The composition of matter of claim ~~[[48]]~~ 37, wherein ~~said at least one compound selected from group (i) (+)-~~ (2R,3R)-1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol is selected from the group consisting of:

- ~~(2RS,3RS) 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol~~
 - ~~(2R,3R) 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,~~
 - ~~(+)-(2R,3R) 1-dimethylamino-3-(3-methoxy-phenyl)-2-methyl-pentan-3-ol,~~
 - ~~(2RS,3RS) 4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol, and~~
 - ~~(+)-(2R,3R) 4-dimethylamino-2-(3-methoxy-phenyl)-3-methyl-butan-2-ol,~~
- and in the form of a hydrochloride salt salts of the foregoing.

58-72. (canceled)

73. (previously presented) A pharmaceutical formulation comprising as an active compound combination a composition of matter according to claim 37 and at least one pharmaceutically suitable additive or auxiliary substance.